NKTR Stock Price Nektar Therapeutics Stock Quote U S.: Nasdaq

This Gold-rated large-cap fund’s multimanager approach has richly rewarded investors. Investors remained cautiously optimistic despite looming threats and rocky markets. By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan’s own foreign minister is saying that China is on the cusp of a full scale invasion.

Intraday Data provided by FACTSET and subject to terms of use. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. According to 16 stock analysts, the average 12-month stock price forecast for NKTR stock is $2.99, which predicts an increase of 219.24%. In conclusion, Nektar Therapeutics has seen bad performance in recent times.

Recently Viewed Tickers

More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.

Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?

The simple moving average for the last 20 days is -11.09% for NKTR stock, with a simple moving average of -74.31% for the last 200 days. The chart below shows how a company’s share price and consensus price target have changed over time. The lighter blue line represents the stock’s consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

This suggests a possible upside of 271.5% from the stock’s current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts. 6 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Nektar Therapeutics in the last twelve months. There are currently 3 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” NKTR shares.

Nektar Therapeutics Dropped from S&P SmallCap 600

The Style Scores are a complementary set of indicators to use alongside the https://1investing.in/ Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. LLP6.02Vanguard Health Care Fund6.02PRIMECAP Odyssey Aggressive Growth Fund5.21First Trust Advisors LP4.14First Trust NYSE Arca Biotechnology Index Fund4.12State Street Corp.3.88BlackRock Institutional Trust Co. NA3.39Vanguard Total Stock Market Index Fund3.09Shareholder percentage totals can add to more than 100% because some holders are included in the free float. NewsHeater is specialized on the investments in tech sphere.

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.

The what’s the smallest number of shares i can buy‘s research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. Analysts have forecast the company to bring in revenue of $22.67 million for the current quarter, with the likely lows of $19.38 million and highs of $25 million. The average estimate suggests sales will likely down by -8.70% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2023 is $89.39 million.

We see that NKTR’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell. StockInvest.us is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon StockInvest.us.

Miroslav Gasparek is on a mission to use synbio to change that. His company Sensible Biotechnologies is partnering with Ginkgo Bioworks to develop the next generation of mRNA therapeutics. All values as of most recently reported quarter unless otherwise noted. A lot of important data gets lost along the sales pipeline because sales teams use multiple tools, including email, Zoom and WhatsApp, to talk with buyers.

Over the previous 90 days, Nektar Therapeutics’s stock had 1 downgrade by analysts. Analysts like Nektar Therapeutics less than other Medical companies. The consensus rating for Nektar Therapeutics is Hold while the average consensus rating for medical companies is Buy. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.

Kotak Mahindra Bank Stock Forecast, “500247” Share Price Prediction Charts

But the good news is, if China invades Taiwan, there is a way to protect yourself. Only 3 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. 36 people have searched for NKTR on MarketBeat in the last 30 days.

Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. 6 Wall Street research analysts have issued 12 month price objectives for Nektar Therapeutics’ shares. On average, they predict the company’s share price to reach $3.08 in the next year.

• The 7 analysts offering 1 year price forecasts for NKTR have a max estimate of — and a min estimate of —.
• If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio.
• Investing.com – U.S. equities were higher at the close on Monday, as gains in the Utilities, Telecoms and Technology sectors propelled shares higher.

One share of NKTR stock can currently be purchased for approximately $0.83. 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company’s employees. Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Nektar Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.